Stem Cell Therapy Market
Stem Cell Therapy Market Size, Share and Industry Analysis Report By Type (Allogeneic and Autologous); By Cell Source (Adipose Tissue-derived MSC, Bone Marrow and Placenta/Umbilical Cord); By Therapeutic Application (Musculoskeletal Disorders, Wounds, Injuries, Cardiovascular Diseases, Surgeries, Inflammatory, Autoimmune Diseases, Neurological Disorders, Acute Graft-Versus-Host Disease (AGVHD), Gastrointestinal Diseases); By End User (Hospitals and Surgical Centers, Therapeutic Companies, Services Companies, and Others) - Forecast Year 2024 – 2031
Healthcare // Biotechnology
The global stem cell therapy market is
foreseen to grow by 17.3%, from USD 239.84 Million in 2022 to USD 859.61
Million in 2030. Availability of funding for stem cell research, increasing GMP
certification approvals for cell therapy production facilities, increasing
clinical trials for stem cell-based therapies is to drive the market for the
upcoming forecast period. However, Ethical concerns related to embryonic stem
cells, high cost of cell-based research remains one factor hindering the market
growth over the anticipated period.
Market Definition
What Is Stem Cell Therapy?
Market Overview
Stem Cell Therapy: An Emerging Treatment
Option for a Wide Range of Medical Conditions
Stem cell therapy is an exciting and rapidly
advancing field of medicine that holds great promise for the treatment of a
wide range of medical conditions. Stem cells are undifferentiated cells that
can differentiate into various types of cells, including muscle, nerve, bone,
and cartilage cells. This makes them a potential source of replacement cells
for damaged tissues and organs.
Stem cell therapy is being investigated as a
treatment option for many diseases and conditions, including Parkinson's
disease, Alzheimer's disease, diabetes, heart disease, and spinal cord
injuries. The therapy involves the use of stem cells to replace or repair
damaged or diseased tissues and organs.
One of the most promising areas of stem cell
therapy is in the treatment of degenerative diseases such as Parkinson's
disease and Alzheimer's disease. In these conditions, the brain cells that
produce the neurotransmitters dopamine and acetylcholine are damaged or
destroyed, leading to a loss of function. Stem cell therapy has the potential
to replace these damaged cells with new healthy cells that can produce the
necessary neurotransmitters.
Stem cell therapy is also being investigated
as a potential treatment for diabetes. In this condition, the body's ability to
produce insulin is impaired, leading to high blood sugar levels. Stem cell
therapy has the potential to generate new insulin-producing cells that can
restore normal insulin production and regulate blood sugar levels.
Another promising area of stem cell therapy
is in the treatment of heart disease. Stem cells have the ability to
differentiate into various types of heart cells, including muscle cells and
blood vessel cells. This makes them a potential source of replacement cells for
damaged heart tissue. In addition, stem cells have been shown to have
anti-inflammatory and immune-regulating properties, which may help reduce
inflammation and improve the healing process in the heart.
Stem cell therapy is also being investigated
as a potential treatment for spinal cord injuries. In these injuries, the nerve
cells that transmit signals between the brain and the body are damaged or
destroyed, leading to paralysis. Stem cell therapy has the potential to replace
these damaged cells with new healthy cells that can restore function and
improve quality of life.
While stem cell therapy holds great promise
for the treatment of a wide range of medical conditions, there are still many
challenges to be overcome. One of the biggest challenges is the risk of
rejection of the transplanted cells by the body's immune system. In addition,
there is still much to be learned about the properties and behavior of stem
cells.
Dynamics of Stem Cell Therapy Market
Drivers in Stem Cell Therapy Market
The stem cell therapy market is driven by the
availability of funding for stem cell research, as it enables the development
of novel therapeutic interventions for various disorders. The funding for stem
cell research has been increasing steadily in recent years, with a year-on-year
growth of over 5%. The rise in funding initiatives is expected to continue
during the forecast period, which will further drive the market growth. The
increasing demand for stem cell banking and the growth of precision medicine
and clinical trials are also contributing to the market growth. Furthermore,
technological advancements in the parent and ancillary markets for stem cell
usage are expected to reinforce the demand for stem cells over the forecast
period. The Therapy Type of stem cells in the treatment of COVID-19 has also
increased the interest of medical researchers, resulting in an increase in
clinical trials.
Restraints in Stem Cell Therapy Market
However, the market growth is restrained by
ethical concerns related to embryonic stem cells. Studies exploring the
therapeutic potential of embryonic stem cells are associated with various
ethical issues related to the destruction of human embryos. The lack of proper
federal policies that define what can be funded in embryo-based stem cell
research or therapy development may limit the market's expansion in the future.
Moreover, regulatory challenges, including issues related to clinical trials,
safety, and efficacy, can be costly and time-consuming. Stem cell research and
therapy can be expensive, and funding can be limited, particularly for
early-stage companies or researchers. Technical limitations related to stem
cell therapy, such as the need for specialized equipment and the difficulty of
scaling up production, can impact the availability and affordability of new
therapies. Finally, the stem cell therapy industry is subject to intellectual
property issues, including challenges related to patent protection, licensing,
and ownership, which can create legal challenges for companies and researchers.
Opportunities in Stem Cell Therapy Market
The global market for stem cell-based
therapies is expected to see significant growth due to their safety and
effectiveness in regenerative medicine. Stem cells have the potential to
replace and heal damaged tissues and organs, making them an attractive source
of treatment for researchers, clinicians, and scientists. The market growth is
being driven by a variety of factors, including increasing collaborations,
robust funding, government initiatives, and extensive research and development.
For example, the CiRA Foundation and CGT Catapult recently launched a
collaborative research project aimed at developing novel methods to
characterize pluripotent stem cells for the manufacturing of regenerative
medicine products.
Significant research and development
investments and the need for effective therapeutics to reduce disease burden
are also contributing to the market's growth. Celavie Biosciences is one such
company working on regenerative stem cell therapies to treat Parkinson's
disease and other central nervous system disorders. The company announced that
their preliminary clinical trials utilizing OK99 stem cells for Parkinson's
disease were successful in May 2020.
Challenges in Stem Cell Therapy Market
However, safety concerns remain one of the
main challenges facing stem cell therapy. There is a risk that transplanted
stem cells may cause immune reactions or form tumors, which can be
life-threatening. Additionally, the cost and accessibility of stem cell therapy
are a challenge, as the treatment is often expensive and not covered by
insurance. Limited clinical trials and research studies can also slow down the
development process and make it difficult to determine the safety and efficacy
of the treatment. Finally, technical challenges remain, such as the ability to
differentiate stem cells into specific cell types, which requires a deep
understanding of stem cell biology and can be challenging in practice.
Ecosystem of Stem Cell Therapy Market
The stem cell therapy market can be divided
into two types: allogeneic and autologous. Of these two, the allogeneic stem
cell therapy segment holds the largest market share. The reason for this is
that the development and manufacturing of allogeneic stem cell therapies have
fewer complications compared to autologous stem cell therapies. As a result,
there has been a significant increase in the number of clinical trials focused
on developing allogeneic stem cell therapies. Due to these factors, the allogeneic
stem cell therapy segment is predicted to be the fastest growing during the
forecast period.
In terms of cell source, the stem cell
therapy market is segmented into adipose tissue-derived MSCs,
placental/umbilical cord-derived MSCs, bone marrow-derived MSCs, and other
sources. Among these, the adipose tissue-derived stem cell segment dominates
the market in terms of revenue share. This is due to their increasing adoption
in various therapeutic indications. The advantages of adipose tissue-derived
MSCs, such as simple isolation procedures, minimally invasive harvesting
methods, and better proliferation capacity, have contributed to their
popularity in the market. As a result, this segment is expected to continue to
grow during the forecast period.
During the stem cell therapy market forecast
period, the major revenue contributor by cell source was the adipose
tissue-derived mesenchymal stem cells segment. This trend is expected to
continue, as there has been an increase in the number of patients suffering from
cancer. The growth of the market can also be attributed to the increasing
target population, exposure to harmful radiation, and favorable government
initiatives. On the other hand, the bone marrow-derived mesenchymal stem cells
segment is projected to exhibit the fastest market growth during the forecast
period, due to a higher incidence of chronic and fatal diseases such as
musculoskeletal diseases, and an increase in smoking tobacco that includes
passive smoking, which may lead to cancer.
The cancer segment was the major revenue
contributor during the forecast period, and it is anticipated to continue this
trend throughout the forecast period due to an increase in the number of
patients suffering from cardiovascular, musculoskeletal, and gastrointestinal
diseases. In addition, the growth of the market is also attributed to the
increase in research and development activities. Autologous transplants are
expected to grow with the largest stem cell therapy market share throughout the
forecast period. This is due to the increase in the use of autologous stem
cells and the availability of a number of stem cell products. Recent advances
in cellular technology have contributed to improving the understanding of
various disease cells and their metabolism at the molecular level, thus driving
the need for stem cell therapies for the treatment of diseases.
he stem cell therapy market is segmented by
therapeutic Therapy Type into musculoskeletal disorders, cardiovascular
diseases, wounds and injuries, neurological disorders, surgeries, inflammatory
and autoimmune diseases, and other therapeutic Therapy Types. The
musculoskeletal disorders segment has generated the highest revenue during the
forecast period, primarily due to the high prevalence of conditions such as osteoarthritis,
coupled with the rising demand for regenerative medicine in orthopedic and
sports medicine Therapy Types.
Market Segmentation
For the purpose of this report, the global stem
cell therapy market segmented on the basis of cell source, therapy type, therapeutic
application, end user, and region:
Cell source Outlook:
On the basis of Cell source, the market is
segmented into Adipose tissue-derived MSCs (mesenchymal stem cells), Bone
marrow-derived MSCs, Placental/umbilical cord-derived MSCs, and, Other Cell
Sources.
Therapy Type Outlook:
On the basis of type, the market is segmented
into allogeneic stem cell therapy, autologous stem cell therapy.
Therapeutic Application Outlook:
On the basis of therapeutic application, the
market is segmented into musculoskeletal disorders, wounds & injuries,
cardiovascular diseases, surgeries, inflammatory & autoimmune diseases,
neurological disorders, other therapeutic applications.
Figure 1 Stem Cell Therapy Market By Therapeutic Application (Market Size And Forecast By Value - USD Million, 2022 & 2030)
End User Outlook:
On the basis of end user, the market is
segmented into hospitals, surgical centers, therapeutic companies, services
companies, others.
Regional Outlook (Revenue, USD Million; 2022 & 2030)
|
Regional Outlook (Revenue, USD Million; 2020-2030) |
|
|
North America |
U.S. |
|
Canada |
|
|
Europe |
Germany |
|
U.K. |
|
|
France |
|
|
Spain |
|
|
Italy |
|
|
Rest of the Europe |
|
|
Asia Pacific |
India |
|
Japan |
|
|
China |
|
|
South Korea |
|
|
Australia |
|
|
Rest of Asia-Pacific |
|
|
Middle East & Africa |
UAE |
|
Saudi Arabia |
|
|
South Africa |
|
|
Rest of Middle East &
Africa |
|
|
Latin America |
Brazil |
|
Mexico |
|
|
Argentina |
|
|
Rest of Latin America |
|
Figure 2 Stem Cell Therapy Market: Regional Dynamics
Geographically, the market is segmented into
North America, Europe, Asia Pacific, and RoW (the rest of the world). North
America is the largest region for the stem cell therapy market, dominating the
market during the forecast period. The United States is a key contributor to
the region's revenue, driven by the availability of public-private funding to
develop innovative stem cell therapy products. This trend is expected to
continue in the coming years.
Regional insights reveal that the global market for stem cell therapy is expected to experience significant growth during the forecast period in Europe, North America, South America, Africa, and APAC. In Europe, it is anticipated that the market will witness a compound annual growth rate (CAGR) of 7.9%. In North America, the market is expected to grow at a CAGR of 8.9%. Meanwhile, the South American market is projected to grow at a CAGR of 7.3%, and the African market is expected to grow at a CAGR of 8.3%. Lastly, the APAC market for stem cell therapy is predicted to witness the highest growth rate, with a CAGR of 9.6% during the forecast period. These insights suggest that the global market for stem cell therapy is expected to experience significant growth in various regions, with the highest growth anticipated in the APAC region.
Companies Considered And Profiled In This Market Study
The players operating in the market have
undertaken several strategies related to the market in the period 2020-2022.
some of the prominent players in the Stem Cell Therapy market include
·
SMITH+NEPHEW
·
MEDIPOST CO., LTD.
·
JCR PHARMACEUTICALS
CO., LTD.
·
TAKEDA
PHARMACEUTICAL COMPANY LIMITED
·
ANTEROGEN. CO.,
LTD.
·
CORESTEM
·
PHARMICELL CO.,
LTD.
·
NUVASIVE, INC.
·
RTI SURGICAL
·
ALLOSOURCE
·
HOLOSTEM TERAPIE
AVANZATE SRL
·
ORTHOFIX
·
STEMPEUTICS
RESEARCH
·
REGROW BIOSCIENCES
PVT LTD.
·
ATHERSYS, INC.
·
MESOBLAST LTD
·
BIORESTORATIVE
THERAPIES, INC.
·
PLURISTEM INC.
·
BRAINSTORM CELL
LIMITED.
·
GAMIDA CELL
·
VIACYTE, INC.
·
KANGSTEM BIOTECH
·
HOPE BIOSCIENCES
·
CELLULAR
BIOMEDICINE GROUP (CBMG)
·
PERSONALIZED STEM
CELLS
·
Allele
Biotechnology and Pharmaceuticals, Inc.
·
Astellas Pharma
Inc.
·
Fujifilm Holding
Corporation
·
Novadip Biosciences
·
U.S. Stem Cell,
Inc.
Global Stem Cell Therapy Market Report Scope
|
Historical data |
2020 - 2022 |
|
Base year for estimation |
2022 |
|
Forecast period |
2023 - 2030 |
|
Market size value in 2022 |
USD 239.84 Million |
|
Revenue forecast in 2030 |
USD 859.61 Million |
|
Growth Rate |
CAGR of 6.6% from 2023 to 2030 |
|
Quantitative units |
Revenue in USD Million/Billion & CAGR from 2023 to 2030 |
|
Report coverage |
Revenue forecast, company share,
competitive landscape, growth factors, and trends |
|
Segments covered |
Cell source, Therapy Type, Therapeutic Application, End User |
|
Key companies profiled |
Smith+Nephew, Medipost Co., Ltd., Jcr
Pharmaceuticals Co., Ltd. |
|
Regional Scope |
North America, Europe, Asia Pacific, Middle East & Africa, Latin
America |
|
Country Scope |
U.S., Canada, Germany, U.K., France, Italy,
Spain, India, Japan, China, Australia, South Korea, Saudi Arabia, UAE, South
Africa, Brazil, Mexico, Argentina |
|
Customization scope |
Free report customization (equivalent to up to 8 analysts’ working
days) with purchase. Addition or alteration to country, regional &
segment scope. |
Cell source Outlook
(Revenue, USD Million/Billion; 2020-2030)
·
Adipose
tissue-derived MSCs (mesenchymal stem cells),
·
Bone marrow-derived
MSCs,
·
Placental/umbilical
cord-derived MSCs, and
·
Other Cell Sources
Therapy Type Outlook
(Revenue, USD Million/Billion; 2020-2030)
·
Allogeneic Stem
Cell Therapy
·
Autologous Stem
Cell Therapy
Therapeutic
Application Outlook (Revenue, USD Million/Billion; 2020-2030)
·
Musculoskeletal
Disorders
·
Wounds &
Injuries
·
Cardiovascular
Diseases
·
Surgeries
·
Inflammatory &
Autoimmune Diseases
·
Neurological
Disorders
·
Other Therapeutic
Applications
End User Outlook
(Revenue, USD Million/Billion; 2020-2030)
·
Hospitals
·
Surgical Centers
·
Therapeutic
Companies
·
Services Companies
·
Others
Regional Outlook (Revenue,
USD Million/Billion; 2020-2030)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
U.K.
o
France
o
Spain
o
Italy
o
Rest of the Europe
·
Asia Pacific
o
India
o
Japan
o
China
o
South Korea
o
Australia
o
Rest of
Asia-Pacific
·
Middle East &
Africa
o
UAE
o
Saudi Arabia
o
South Africa
o
Rest of Middle East
& Africa
·
Latin America
o
Brazil
o
Mexico
o
Argentina
o
Rest of Latin
America
Recent Developments In Stem Cell Therapy Market:
In 2020, Boston-based biotech company
ElevateBio announced the acquisition of UK-based Cell and Gene Therapy Catapult
(CGTC), a leading cell and gene therapy manufacturing center. The acquisition
was aimed at expanding ElevateBio's capabilities in developing and
manufacturing cell and gene therapies, including stem cell therapies.
Also in 2020, California-based biotech
company Sorrento Therapeutics announced a partnership with South Korea-based
biotech company ACEA Therapeutics to develop stem cell therapies for a range of
diseases, including COVID-19. The partnership aimed to leverage ACEA's
expertise in stem cell research and Sorrento's expertise in drug development.
In 2019, Fujifilm Corporation, a Japanese
multinational conglomerate, announced the acquisition of Irvine Scientific
Sales Company, a California-based company specializing in cell culture media
and products for regenerative medicine. The acquisition was aimed at expanding
Fujifilm's capabilities in the development and manufacture of stem cell therapies.
In 2019, Swiss pharmaceutical company
Novartis acquired CellforCure, a French company specializing in cell and gene
therapy manufacturing. The acquisition was aimed at strengthening Novartis'
capabilities in developing and manufacturing stem cell therapies for a range of
diseases.
In January 2021, the Japanese biotech company
FUJIFILM Cellular Dynamics announced its acquisition of the American company
The Automation Partnership (TAP), which specializes in the development of
automation technology for cell and gene therapy manufacturing. The acquisition
will enable FUJIFILM Cellular Dynamics to expand its capabilities in the field
of stem cell therapies.
In July 2020, the German biotech company
BioNTech entered into a partnership with the Chinese biotech company Shanghai
Fosun Pharmaceutical to develop and commercialize its stem cell-based CAR-T
cell therapies in China. The partnership will allow BioNTech to tap into the
rapidly growing Chinese market for cell therapies.
In May 2019, the biotech company Pluristem
Therapeutics announced a strategic partnership with the Abu Dhabi Stem Cells
Center (ADSCC) to advance the development of its placenta-derived cell
therapies for a range of diseases. The partnership will enable Pluristem to
access the ADSCC's expertise in stem cell research and accelerate the
development of its therapies.
In February 2019, the Israeli biotech company
Kadimastem announced a strategic partnership with the Australian biotech
company Regeneus to develop stem cell therapies for the treatment of diabetes
and other diseases. The partnership will combine Kadimastem's expertise in the
development of pancreatic islet cells with Regeneus's expertise in the
development of stem cell therapies.
In September 2018, the Japanese biotech
company Takeda announced its acquisition of the Belgian biotech company
TiGenix, which specializes in the development of allogeneic stem cell therapies
for the treatment of autoimmune and inflammatory diseases. The acquisition will
enable Takeda to expand its capabilities in the field of regenerative medicine.
|
Chapter
1. Introduction |
|
|
1.1. Market Definition |
|
|
1.2. Research Scope |
|
|
1.2.1. Markets Covered |
|
|
1.2.2. Years Considered for
Study |
|
|
Chapter
2. Executive Summary |
|
|
2.1. Summary Snapshot Market Size
and Forecast, 2020-2030 |
|
|
2.2. Stem Cell Therapy Market Share by
Cell source, 2022 vs 2030 (USD Million) |
|
|
2.3. Stem Cell Therapy Market Share by
Type, 2022 vs 2030 (USD Million) |
|
|
2.4. Stem Cell Therapy Market Share by
Therapeutic Application, 2022 vs 2030 (USD Million) |
|
|
2.5. Stem Cell Therapy Market Share by
End User, 2022 vs 2030 (USD Million) |
|
|
2.6. Stem Cell Therapy Market Share by
Region, 2022 vs 2030 (USD Million) |
|
|
Chapter
3. Key Insights |
|
|
Chapter
4. Stem Cell Therapy Market Segmentation & Impact Analysis |
|
|
4.1. Stem Cell Therapy Market Indicators
Analysis |
|
|
4.1.1. Market Drivers
Analysis |
|
|
4.1.1.1. Availability
of funding for stem cell research |
|
|
4.1.1.2. Increasing
GMP certification approvals for cell therapy production facilities |
|
|
4.1.1.3. Increasing
clinical trials for stem cell-based therapies |
|
|
4.1.2. Market Restraint
Analysis |
|
|
4.1.2.1.
Ethical concerns related to embryonic stem cells |
|
|
4.1.2.2. High cost
of cell-based research |
|
|
4.1.3. Market Opportunity
Analysis |
|
|
4.1.3.1. Emergence
of iPSCs as an alternative to ESCs |
|
|
4.1.3.2.
Growing demand for cell & gene therapies |
|
|
4.2. Regulatory Analysis |
|
|
4.2.1. North America |
|
|
4.2.1.1. U.S. |
|
|
4.2.1.2. Canada |
|
|
4.2.2. Europe |
|
|
4.2.3. Asia Pacific |
|
|
4.2.3.1. India |
|
|
4.2.3.2. Japan |
|
|
4.2.3.3. China |
|
|
4.3. Technological Insights |
|
|
4.4. COVID-19 Impact analysis on Stem
Cell Therapy Market |
|
|
4.5. Porter’s Five Forces Analysis |
|
|
4.5.1. Bargaining Power of
Buyers/Consumers |
|
|
4.5.2. Bargaining Power of
Suppliers |
|
|
4.5.3. Threat of New Entrants |
|
|
4.5.4. Threat of Substitute
Products |
|
|
4.5.5. Intensity of Competitive
Rivalry |
|
|
4.6. Competitive Metric Space Analysis |
|
|
Chapter
5. Stem Cell Therapy Market, By Cell source (Market Size and Forecast by
Value - USD Million, 2020 - 2030) |
|
|
5.1. Stem Cell Therapy Market, By Cell
source (Market Size and Forecast by Value - USD Million, 2022 & 2030) |
|
|
5.1.1. Adipose tissue-derived
MSCs (mesenchymal stem cells), |
|
|
5.1.1.1. Adipose tissue-derived MSCs (mesenchymal
stem cells), Market Estimates and Forecast, 2020-2030 (USD Million) |
|
|
5.1.1.2. Adipose tissue-derived MSCs (mesenchymal
stem cells), Market Estimates and Forecast, By Region, 2020-2030 (USD
Million) |
|
|
5.1.2. Bone marrow-derived
MSCs, |
|
|
5.1.2.1. Bone
marrow-derived MSCs, Market Estimates and Forecast, 2020-2030 (USD Million) |
|
|
5.1.2.2. Bone
marrow-derived MSCs, Market Estimates and Forecast, By Region, 2020-2030 (USD
Million) |
|
|
5.1.3. Placental/umbilical
cord-derived MSCs, and |
|
|
5.1.3.1.
Placental/umbilical cord-derived MSCs, and Market Estimates and Forecast,
2020-2030 (USD Million) |
|
|
5.1.3.2.
Placental/umbilical cord-derived MSCs, and Market Estimates and Forecast, By
Region, 2020-2030 (USD Million) |
|
|
5.1.4. Other Cell Sources |
|
|
5.1.4.1. Other Cell
Sources Market Estimates and Forecast, 2020-2030 (USD Million) |
|
|
5.1.4.2. Other Cell Sources
Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
|
Chapter
6. Stem Cell Therapy Market, By Type (Market Size and Forecast by Value
- USD Million, 2020 - 2030) |
|
|
6.1. Stem Cell Therapy Market, By Type
(Market Size and Forecast by Value - USD Million, 2022 & 2030) |
|
|
6.1.1. Allogeneic Stem Cell
Therapy |
|
|
6.1.1.1. Allogeneic Stem Cell Therapy Market
Estimates and Forecast, 2020-2030 (USD Million) |
|
|
6.1.1.2. Allogeneic Stem Cell Therapy Market
Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
|
6.1.2. Autologous Stem Cell
Therapy |
|
|
6.1.2.1. Autologous Stem Cell Therapy Market Estimates
and Forecast, 2020-2030 (USD Million) |
|
|
6.1.2.2. Autologous Stem Cell Therapy Market
Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
|
Chapter
7. Stem Cell Therapy Market, By Therapeutic Application (Market Size and
Forecast by Value - USD Million, 2020 - 2030) |
|
|
7.1. Stem Cell Therapy Market, By
Therapeutic Application (Market Size and Forecast by Value - USD Million,
2022 & 2030) |
|
|
7.1.1. Musculoskeletal
Disorders |
|
|
7.1.1.1. Musculoskeletal Disorders Market Estimates
and Forecast, 2020-2030 (USD Million) |
|
|
7.1.1.2. Musculoskeletal Disorders Market Estimates
and Forecast, By Region, 2020-2030 (USD Million) |
|
|
7.1.2. Wounds & Injuries |
|
|
7.1.2.1. Wounds & Injuries Market Estimates and
Forecast, 2020-2030 (USD Million) |
|
|
7.1.2.2. Wounds & Injuries Market Estimates and
Forecast, By Region, 2020-2030 (USD Million) |
|
|
7.1.3. Cardiovascular Diseases |
|
|
7.1.3.1.
Cardiovascular Diseases Market Estimates and Forecast, 2020-2030 (USD
Million) |
|
|
7.1.3.2.
Cardiovascular Diseases Market Estimates and Forecast, By Region, 2020-2030
(USD Million) |
|
|
7.1.4. Surgeries |
|
|
7.1.4.1. Surgeries
Market Estimates and Forecast, 2020-2030 (USD Million) |
|
|
7.1.4.2. Surgeries
Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
|
7.1.5. Inflammatory &
Autoimmune Diseases |
|
|
7.1.5.1.
Inflammatory & Autoimmune Diseases Market Estimates and Forecast,
2020-2030 (USD Million) |
|
|
7.1.5.2.
Inflammatory & Autoimmune Diseases Market Estimates and Forecast, By
Region, 2020-2030 (USD Million) |
|
|
7.1.6. Neurological Disorders |
|
|
7.1.6.1.
Inflammatory & Autoimmune Diseases Market Estimates and Forecast,
2020-2030 (USD Million) |
|
|
7.1.6.2.
Inflammatory & Autoimmune Diseases Market Estimates and Forecast, By
Region, 2020-2030 (USD Million) |
|
|
7.1.7. Other Therapeutic
Applications |
|
|
7.1.7.1.
Inflammatory & Autoimmune Diseases Market Estimates and Forecast,
2020-2030 (USD Million) |
|
|
7.1.7.2.
Inflammatory & Autoimmune Diseases Market Estimates and Forecast, By
Region, 2020-2030 (USD Million) |
|
|
Chapter
8. Stem Cell Therapy Market, By End User (Market Size and Forecast by
Value - USD Million, 2020 - 2030) |
|
|
8.1. Stem Cell Therapy Market, By End User
(Market Size and Forecast by Value - USD Million, 2022 & 2030) |
|
|
8.1.1. Hospitals |
|
|
8.1.1.1. Hospitals Market Estimates and Forecast,
2020-2030 (USD Million) |
|
|
8.1.1.2. Hospitals Market Estimates and Forecast, By
Region, 2020-2030 (USD Million) |
|
|
8.1.2. Surgical Centers |
|
|
8.1.2.1. Surgical Centers Market Estimates and
Forecast, 2020-2030 (USD Million) |
|
|
8.1.2.2. Surgical Centers Market Estimates and
Forecast, By Region, 2020-2030 (USD Million) |
|
|
8.1.3. Therapeutic Companies |
|
|
8.1.3.1. Therapeutic
Companies Market Estimates and Forecast, 2020-2030 (USD Million) |
|
|
8.1.3.2. Therapeutic
Companies Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
|
8.1.4. Services Companies |
|
|
8.1.4.1. Services Companies Market
Estimates and Forecast, 2020-2030 (USD Million) |
|
|
8.1.4.2. Services
Companies Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
|
8.1.5. Others |
|
|
8.1.5.1. Others Market Estimates and
Forecast, 2020-2030 (USD Million) |
|
|
8.1.5.2. Others
Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
|
Chapter
9. Stem Cell Therapy Market, By Region (Market Size and Forecast by Value -
USD Million, 2020 - 2030) |
|
|
9.1. Stem Cell Therapy Market, By
Region (Market Size and Forecast by Value - USD Million, 2022 & 2030) |
|
|
9.2. North America |
|
|
9.2.1. North America Stem Cell
Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.2.2. North America Stem Cell
Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.2.3. North America Stem Cell
Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.2.4. North America Stem Cell
Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.2.5. North America Stem Cell Therapy
Market, By Country, 2020-2030 (USD Million) |
|
|
9.2.6. U.S. |
|
|
9.2.6.1. U.S.
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.2.6.2. U.S.
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.2.6.3. U.S.
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.2.6.4. U.S.
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.2.7. Canada |
|
|
9.2.7.1. Canada
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.2.7.2. Canada
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.2.7.3. Canada
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.2.7.4. Canada Stem
Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.3. Europe |
|
|
9.3.1. Europe Stem Cell Therapy
Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.3.2. Europe Stem Cell Therapy
Market, By Type, 2020-2030 (USD Million) |
|
|
9.3.3. Europe Stem Cell Therapy
Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.3.4. EuropeStem Cell Therapy
Market, By End User, 2020-2030 (USD Million) |
|
|
9.3.5. Europe Stem Cell Therapy
Market, By Country, 2020-2030 (USD Million) |
|
|
9.3.6. Germany |
|
|
9.3.6.1. Germany
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.3.6.2. Germany Stem
Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.3.6.3. Germany
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.3.6.4. Germany
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.3.7. U.K. |
|
|
9.3.7.1. U.K.
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.3.7.2. U.K. Stem
Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.3.7.3. U.K.
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.3.7.4. U.K. Stem
Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.3.8. France |
|
|
9.3.8.1. France
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.3.8.2. France
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.3.8.3. France
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.3.8.4. France
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.3.9. Spain |
|
|
9.3.9.1. Spain
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.3.9.2. Spain
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.3.9.3. Spain
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.3.9.4. Spain Stem
Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.3.10. Italy |
|
|
9.3.10.1. Italy
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.3.10.2. Italy
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.3.10.3. Italy
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.3.10.4. Italy
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.3.11. Rest of Europe |
|
|
9.3.11.1. Rest of
Europe Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.3.11.2. Rest of
Europe Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.3.11.3. Rest of
Europe Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD
Million) |
|
|
9.3.11.4. Rest of
Europe Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.4. Asia Pacific |
|
|
9.4.1. Asia Pacific Stem Cell
Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.4.2. Asia Pacific Stem Cell
Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.4.3. Asia Pacific Stem Cell
Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.4.4. Asia Pacific Stem Cell
Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.4.5. Asia Pacific Stem Cell Therapy
Market, By Country, 2020-2030 (USD Million) |
|
|
9.4.6. India |
|
|
9.4.6.1. India
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.4.6.2. India
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.4.6.3. India
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.4.6.4. India
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.4.7. Japan |
|
|
9.4.7.1. Japan
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.4.7.2. Japan Stem
Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.4.7.3. Japan
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.4.7.4. Japan
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.4.8. China |
|
|
9.4.8.1. China
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.4.8.2. China
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.4.8.3. China
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.4.8.4. China
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.4.9. South Korea |
|
|
9.4.9.1. South
Korea Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.4.9.2. South Korea
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.4.9.3. South
Korea Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD
Million) |
|
|
9.4.9.4. South
Korea Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.4.10. Australia |
|
|
9.4.10.1.
Australia Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.4.10.2.
Australia Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.4.10.3.
Australia Stem Cell Therapy Market, By Therapeutic Application, 2020-2030
(USD Million) |
|
|
9.4.10.4. Australia
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.4.11. Rest of Asia Pacific |
|
|
9.4.11.1. Rest of
Asia Pacific Stem Cell Therapy Market, By Cell source, 2020-2030 (USD
Million) |
|
|
9.4.11.2. Rest of Asia
Pacific Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.4.11.3. Rest of
Asia Pacific Stem Cell Therapy Market, By Therapeutic Application, 2020-2030
(USD Million) |
|
|
9.4.11.4. Rest of Asia
Pacific Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.5. Middle East & Africa |
|
|
9.5.1. Middle East & Africa
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.5.2. Middle East & Africa
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.5.3. Middle East & Africa
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.5.4. Middle East & Africa
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.5.5. Middle East & Africa
Stem Cell Therapy Market, By Country, 2020-2030 (USD Million) |
|
|
9.5.6. UAE |
|
|
9.5.6.1. UAE Stem
Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.5.6.2. UAE Stem
Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.5.6.3. UAE Stem
Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.5.6.4. UAE Stem
Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.5.7. Saudi Arabia |
|
|
9.5.7.1. Saudi
Arabia Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.5.7.2. Saudi
Arabia Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.5.7.3. Saudi
Arabia Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD
Million) |
|
|
9.5.7.4. Saudi
Arabia Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.5.8. South Africa |
|
|
9.5.8.1. South
Africa Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.5.8.2. South Africa
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.5.8.3. South Africa
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.5.8.4. South
Africa Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.5.9. Rest of Middle East
& Africa |
|
|
9.5.9.1. Rest of
Middle East & Africa Stem Cell Therapy Market, By Cell source, 2020-2030
(USD Million) |
|
|
9.5.9.2. Rest of
Middle East & Africa Stem Cell Therapy Market, By Type, 2020-2030 (USD
Million) |
|
|
9.5.9.3. Rest of
Middle East & Africa Stem Cell Therapy Market, By Therapeutic
Application, 2020-2030 (USD Million) |
|
|
9.5.9.4. Rest of
Middle East & Africa Stem Cell Therapy Market, By End User, 2020-2030
(USD Million) |
|
|
9.6. Latin America |
|
|
9.6.1. Latin America Stem Cell
Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.6.2. Latin America Stem Cell Therapy
Market, By Type, 2020-2030 (USD Million) |
|
|
9.6.3. Latin America Stem Cell
Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.6.4. Latin America Stem Cell
Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.6.5. Latin America Stem Cell
Therapy Market, By Country, 2020-2030 (USD Million) |
|
|
9.6.6. Brazil |
|
|
9.6.6.1. Brazil Stem
Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.6.6.2. Brazil
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.6.6.3. Brazil Stem
Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.6.6.4. Brazil
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.6.7. Mexico |
|
|
9.6.7.1. Mexico
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.6.7.2. Mexico
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.6.7.3. Mexico
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.6.7.4. Mexico
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.6.8. Argentina |
|
|
9.6.8.1.
Argentina Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.6.8.2.
Argentina Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.6.8.3. Argentina
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.6.8.4.
Argentina Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
9.6.9. Rest of Latin America |
|
|
9.6.9.1. Rest of Latin
America Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
|
9.6.9.2. Rest of
Latin America Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
|
9.6.9.3. Rest of Latin America Stem
Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
|
9.6.9.4. Rest of
Latin America Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
|
Chapter
10. Competitive Landscape |
|
|
10.1. Market Revenue Share by
Manufacturers |
|
|
10.2. Competitor’s Positioning |
|
|
10.3. Strategy Benchmarking |
|
|
10.3.1. Partnership &
Agreement |
|
|
10.3.2. New Product Development |
|
|
10.3.3. Mergers &
Acquisitions |
|
|
10.3.4. Investment &
Expansion |
|
|
10.4. Vendor Landscape |
|
|
10.4.1. Distributors |
|
|
10.4.2. North America |
|
|
10.4.3. Europe |
|
|
10.4.4. Asia Pacific |
|
|
10.4.5. Middle East &
Africa |
|
|
10.4.6. Latin America |
|
|
10.5. Zettabyte Analytics Insights for
Competitive Landscape |
|
|
Chapter
11. Company Profiles |
|
|
11.1. Allele Biotechnology And
Pharmaceuticals, Inc. |
|
|
11.1.1. Company Overview |
|
|
11.1.2. Products Offered |
|
|
11.1.3. Financials |
|
|
11.1.4. Recent
Development |
|
|
11.2. Allosource |
|
|
11.2.1. Company Overview |
|
|
11.2.2. Products Offered |
|
|
11.2.3. Financials |
|
|
11.2.4. Recent
Development |
|
|
11.3. Anterogen. Co., Ltd. |
|
|
11.3.1. Company Overview |
|
|
11.3.2. Products Offered |
|
|
11.3.3. Financials |
|
|
11.3.4. Recent
Development |
|
|
11.4. Astellas Pharma Inc. |
|
|
11.4.1. Company Overview |
|
|
11.4.2. Products Offered |
|
|
11.4.3. Financials |
|
|
11.4.4. Recent
Development |
|
|
11.5. Athersys, Inc. |
|
|
11.5.1. Company Overview |
|
|
11.5.2. Products Offered |
|
|
11.5.3. Financials |
|
|
11.5.4. Recent
Development |
|
|
11.6. Biorestorative Therapies, Inc. |
|
|
11.6.1. Company Overview |
|
|
11.6.2. Products Offered |
|
|
11.6.3. Financials |
|
|
11.6.4. Recent
Development |
|
|
11.7. Brainstorm Cell Limited. |
|
|
11.7.1. Company Overview |
|
|
11.7.2. Products Offered |
|
|
11.7.3. Financials |
|
|
11.7.4. Recent
Development |
|
|
11.8. Cellular Biomedicine Group (Cbmg) |
|
|
11.8.1. Company Overview |
|
|
11.8.2. Products Offered |
|
|
11.8.3. Financials |
|
|
11.8.4. Recent
Development |
|
|
11.9. Corestem |
|
|
11.9.1. Company Overview |
|
|
11.9.2. Products Offered |
|
|
11.9.3. Financials |
|
|
11.9.4. Recent
Development |
|
|
11.10. Fujifilm Holding Corporation |
|
|
11.10.1. Company Overview |
|
|
11.10.2. Products Offered |
|
|
11.10.3. Financials |
|
|
11.10.4. Recent
Development |
|
|
11.11. Gamida Cell |
|
|
11.11.1. Company Overview |
|
|
11.11.2. Products Offered |
|
|
11.11.3. Financials |
|
|
11.11.4. Recent Development |
|
|
11.12. Holostem Terapie Avanzate Srl |
|
|
11.12.1. Company Overview |
|
|
11.12.2. Products Offered |
|
|
11.12.3. Financials |
|
|
11.12.4. Recent
Development |
|
|
11.13. Hope Biosciences |
|
|
11.13.1. Company Overview |
|
|
11.13.2. Products Offered |
|
|
11.13.3. Financials |
|
|
11.13.4. Recent
Development |
|
|
11.14. Jcr Pharmaceuticals Co., Ltd. |
|
|
11.14.1. Company Overview |
|
|
11.14.2. Products Offered |
|
|
11.14.3. Financials |
|
|
11.14.4. Recent
Development |
|
|
11.15. Kangstem Biotech |
|
|
11.15.1. Company Overview |
|
|
11.15.2. Products Offered |
|
|
11.15.3. Financials |
|
|
11.15.4. Recent
Development |
|
|
11.16. Medipost Co., Ltd. |
|
|
11.16.1. Company Overview |
|
|
11.16.2. Products Offered |
|
|
11.16.3. Financials |
|
|
11.16.4. Recent
Development |
|
|
11.17. Mesoblast Ltd |
|
|
11.17.1. Company Overview |
|
|
11.17.2. Products Offered |
|
|
11.17.3. Financials |
|
|
11.17.4. Recent Development |
|
|
11.18. Novadip Biosciences |
|
|
11.18.1. Company Overview |
|
|
11.18.2. Products Offered |
|
|
11.18.3. Financials |
|
|
11.18.4. Recent
Development |
|
|
11.19. Nuvasive, Inc. |
|
|
11.19.1. Company Overview |
|
|
11.19.2. Products Offered |
|
|
11.19.3. Financials |
|
|
11.19.4. Recent
Development |
|
|
11.20. Orthofix |
|
|
11.20.1. Company Overview |
|
|
11.20.2. Products Offered |
|
|
11.20.3. Financials |
|
|
11.20.4. Recent
Development |
|
|
11.21. Personalized Stem Cells |
|
|
11.21.1. Company Overview |
|
|
11.21.2. Products Offered |
|
|
11.21.3. Financials |
|
|
11.21.4. Recent
Development |
|
|
11.22. Pharmicell Co., Ltd. |
|
|
11.22.1. Company Overview |
|
|
11.22.2. Products Offered |
|
|
11.22.3. Financials |
|
|
11.22.4. Recent Development |
|
|
11.23. Pluristem Inc. |
|
|
11.23.1. Company Overview |
|
|
11.23.2. Products Offered |
|
|
11.23.3. Financials |
|
|
11.23.4. Recent
Development |
|
|
11.24. Regrow Biosciences Pvt Ltd. |
|
|
11.24.1. Company Overview |
|
|
11.24.2. Products Offered |
|
|
11.24.3. Financials |
|
|
11.24.4. Recent
Development |
|
|
11.25. Rti Surgical |
|
|
11.25.1. Company Overview |
|
|
11.25.2. Products Offered |
|
|
11.25.3. Financials |
|
|
11.25.4. Recent
Development |
|
|
11.26. Smith+Nephew |
|
|
11.26.1. Company Overview |
|
|
11.26.2. Products Offered |
|
|
11.26.3. Financials |
|
|
11.26.4. Recent
Development |
|
|
11.27. Stempeutics Research |
|
|
11.27.1. Company Overview |
|
|
11.27.2. Products Offered |
|
|
11.27.3. Financials |
|
|
11.27.4. Recent
Development |
|
|
11.28. Takeda Pharmaceutical Company
Limited |
|
|
11.28.1. Company Overview |
|
|
11.28.2. Products Offered |
|
|
11.28.3. Financials |
|
|
11.28.4. Recent
Development |
|
|
11.29. U.S. Stem Cell, Inc. |
|
|
11.29.1. Company Overview |
|
|
11.29.2. Products Offered |
|
|
11.29.3. Financials |
|
|
11.29.4. Recent Development |
|
|
11.30. Viacyte, Inc. |
|
|
11.30.1. Company Overview |
|
|
11.30.2. Products Offered |
|
|
11.30.3. Financials |
|
|
11.30.4. Recent
Development |
|
|
Chapter
12. Research Methodology |
|
|
12.1. Research Sources |
|
|
12.1.1. Primary |
|
|
12.1.2. Secondary |
|
|
12.12. Market Size Estimation |
|
|
Chapter
13. Appendix |
|
|
13.1.
Discussion guide |
|
|
13.2. Knowledge
Store: Zettabyte Analytics Subscription Portal |
|
|
13.3.
Available Customizations |
|
|
13.4.
Associated Zettabyte Analytics Reports |
|
|
List of
Tables |
|
|
Table 1 |
Stem Cell
Therapy Market, By Cell source (Market Size and Forecast by Value - USD
Million, 2022 & 2030) |
|
Table 2 |
Adipose
tissue-derived MSCs (mesenchymal stem cells), Market Estimates and Forecast,
2020-2030 (USD Million) |
|
Table 3 |
Adipose
tissue-derived MSCs (mesenchymal stem cells), Market Estimates and Forecast,
By Region, 2020-2030 (USD Million) |
|
Table 4 |
Bone
marrow-derived MSCs, Market Estimates and Forecast, 2020-2030 (USD Million) |
|
Table 5 |
Bone
marrow-derived MSCs, Market Estimates and Forecast, By Region, 2020-2030 (USD
Million) |
|
Table 6 |
Stem Cell
Therapy Market, By Type (Market Size and Forecast by Value - USD Million,
2022 & 2030) |
|
Table 7 |
Allogeneic
Stem Cell Therapy Market Estimates and Forecast, 2020-2030 (USD Million) |
|
Table 8 |
Allogeneic
Stem Cell Therapy Market Estimates and Forecast, By Region, 2020-2030 (USD
Million) |
|
Table 9 |
Stem Cell
Therapy Market, By Therapeutic Application (Market Size and Forecast by Value
- USD Million, 2022 & 2030) |
|
Table 10 |
Musculoskeletal
Disorders Market Estimates and Forecast, 2020-2030 (USD Million) |
|
Table 11 |
Musculoskeletal
Disorders Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
Table 12 |
Wounds
& Injuries Market Estimates and Forecast, 2020-2030 (USD Million) |
|
Table 13 |
Wounds
& Injuries Market Estimates and Forecast, By Region, 2020-2030 (USD
Million) |
|
Table 14 |
Cardiovascular
Diseases Market Estimates and Forecast, 2020-2030 (USD Million) |
|
Table 15 |
Cardiovascular
Diseases Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
Table 16 |
Stem Cell
Therapy Market, By End User (Market Size and Forecast by Value - USD Million,
2022 & 2030) |
|
Table 17 |
Hospitals
Market Estimates and Forecast, 2020-2030 (USD Million) |
|
Table 18 |
Hospitals
Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
Table 19 |
Surgical
Centers Market Estimates and Forecast, 2020-2030 (USD Million) |
|
Table 20 |
Surgical
Centers Market Estimates and Forecast, By Region, 2020-2030 (USD Million) |
|
Table 21 |
North
America Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 22 |
North
America Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 23 |
North
America Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD
Million) |
|
Table 24 |
North
America Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 25 |
North
America Stem Cell Therapy Market, By Country, 2020-2030 (USD Million) |
|
Table 26 |
U.S. Stem
Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 27 |
U.S. Stem
Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 28 |
U.S. Stem
Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 29 |
U.S. Stem
Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 30 |
Canada
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 31 |
Canada
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 32 |
Canada
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 33 |
Canada
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 34 |
Europe
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 35 |
Europe
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 36 |
Europe
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 37 |
Europe Stem
Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 38 |
Europe
Stem Cell Therapy Market, By Country, 2020-2030 (USD Million) |
|
Table 39 |
Germany
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 40 |
Germany
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 41 |
Germany
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 42 |
Germany
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 43 |
U.K. Stem
Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 44 |
U.K. Stem
Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 45 |
U.K. Stem
Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 46 |
U.K. Stem
Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 47 |
France
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 48 |
France
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 49 |
France
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 50 |
France
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 51 |
Spain Stem
Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 52 |
Spain
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 53 |
Spain
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 54 |
Spain
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 55 |
Italy
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 56 |
Italy
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 57 |
Italy
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 58 |
Italy
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 59 |
Rest of Europe
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 60 |
Rest of
Europe Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 61 |
Rest of
Europe Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD
Million) |
|
Table 62 |
Rest of
Europe Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 63 |
Asia
Pacific Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 64 |
Asia
Pacific Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 65 |
Asia
Pacific Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD
Million) |
|
Table 66 |
Asia
Pacific Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 67 |
Asia
Pacific Stem Cell Therapy Market, By Country, 2020-2030 (USD Million) |
|
Table 68 |
India
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 69 |
India
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 70 |
India
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 71 |
India
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 72 |
Japan
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 73 |
Japan
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 74 |
Japan
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 75 |
Japan
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 76 |
China
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 77 |
China
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 78 |
China
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 79 |
China
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 80 |
South
Korea Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 81 |
South
Korea Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 82 |
South
Korea Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD
Million) |
|
Table 83 |
South
Korea Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 84 |
Australia
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 85 |
Australia
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 86 |
Australia
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 87 |
Australia
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 88 |
Rest of
Asia Pacific Stem Cell Therapy Market, By Cell source, 2020-2030 (USD
Million) |
|
Table 89 |
Rest of
Asia Pacific Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 90 |
Rest of
Asia Pacific Stem Cell Therapy Market, By Therapeutic Application, 2020-2030
(USD Million) |
|
Table 91 |
Rest of
Asia Pacific Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 92 |
Middle
East & Africa Stem Cell Therapy Market, By Cell source, 2020-2030 (USD
Million) |
|
Table 93 |
Middle
East & Africa Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 94 |
Middle
East & Africa Stem Cell Therapy Market, By Therapeutic Application,
2020-2030 (USD Million) |
|
Table 95 |
Middle
East & Africa Stem Cell Therapy Market, By End User, 2020-2030 (USD
Million) |
|
Table 96 |
Middle
East & Africa Stem Cell Therapy Market, By Country, 2020-2030 (USD
Million) |
|
Table 97 |
UAE Stem
Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 98 |
UAE Stem
Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 99 |
UAE Stem
Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 100 |
UAE Stem
Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 101 |
Saudi
Arabia Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 102 |
Saudi
Arabia Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 103 |
Saudi
Arabia Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD
Million) |
|
Table 104 |
Saudi
Arabia Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 105 |
South
Africa Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 106 |
South
Africa Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 107 |
South
Africa Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD
Million) |
|
Table 108 |
South
Africa Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 109 |
Rest of
Middle East & Africa Stem Cell Therapy Market, By Cell source, 2020-2030
(USD Million) |
|
Table 110 |
Rest of
Middle East & Africa Stem Cell Therapy Market, By Type, 2020-2030 (USD
Million) |
|
Table 111 |
Rest of
Middle East & Africa Stem Cell Therapy Market, By Therapeutic
Application, 2020-2030 (USD Million) |
|
Table 112 |
Rest of
Middle East & Africa Stem Cell Therapy Market, By End User, 2020-2030
(USD Million) |
|
Table 113 |
Latin
America Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 114 |
Latin
America Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 115 |
Latin
America Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD
Million) |
|
Table 116 |
Latin
America Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 117 |
Latin
America Stem Cell Therapy Market, By Country, 2020-2030 (USD Million) |
|
Table 118 |
Brazil
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 119 |
Brazil
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 120 |
Brazil
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 121 |
Brazil
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 122 |
Mexico
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 123 |
Mexico
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 124 |
Mexico
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 125 |
Mexico
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 126 |
Argentina
Stem Cell Therapy Market, By Cell source, 2020-2030 (USD Million) |
|
Table 127 |
Argentina
Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 128 |
Argentina
Stem Cell Therapy Market, By Therapeutic Application, 2020-2030 (USD Million) |
|
Table 129 |
Argentina
Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 130 |
Rest of
Latin America Stem Cell Therapy Market, By Cell source, 2020-2030 (USD
Million) |
|
Table 131 |
Rest of
Latin America Stem Cell Therapy Market, By Type, 2020-2030 (USD Million) |
|
Table 132 |
Rest of
Latin America Stem Cell Therapy Market, By Therapeutic Application, 2020-2030
(USD Million) |
|
Table 133 |
Rest of
Latin America Stem Cell Therapy Market, By End User, 2020-2030 (USD Million) |
|
Table 134 |
Product
Launch & Development in The Stem Cell Therapy Market, 2020-2022 |
|
Table 135 |
Investment
and Expansion in The Stem Cell Therapy Market, 2020-2022 |
|
Table 136 |
Partnership
& Collaboration in The Stem Cell Therapy Market, 2020-2022 |
|
Table 137 |
Merger
& Acquisition in The Stem Cell Therapy Market, 2020-2022 |
|
List of
Figures |
|
|
Figure 1 |
Research
Methodology |
|
Figure 2 |
Summary
Snapshot Market Size and Forecast, USD Million, 2022 & 2030 |
|
Figure 3 |
Global
Stem Cell Therapy Market Segmentation & Impact Analysis |
|
Figure 4 |
Regulatory
Analysis |
|
Figure 5 |
COVID-19
Impact analysis on Stem Cell Therapy Market |
|
Figure 6 |
Market
Revenue Share by Manufacturers |
|
Figure 7 |
Stem Cell
Therapy Market, By Cell source (Market Size and Forecast by Value - USD
Million, 2022 & 2030) |
|
Figure 8 |
Stem Cell
Therapy Market, By Type (Market Size and Forecast by Value - USD Million,
2022 & 2030) |
|
Figure 9 |
Stem Cell
Therapy Market, By Therapeutic Application (Market Size and Forecast by Value
- USD Million, 2022 & 2030) |
|
Figure 10 |
Stem Cell
Therapy Market, By End User (Market Size and Forecast by Value - USD Million,
2022 & 2030) |
|
Figure 11 |
Stem Cell
Therapy Market, By Region (Market Size and Forecast by Value - USD Million,
2022 & 2030) |
1.
Research Sources
We at Zettabyte Analytics have a
detailed and related research methodology focussed on estimating the market
size and forecasted value for the given market. Comprehensive research
objectives and scope were obtained through secondary research of the parent and
peer markets. The next step was to validate our research by various market
models and primary research. Both top-down and bottom-up approaches were
employed to estimate the market. In addition to all the research reports, data
triangulation is one of the procedures used to evaluate the market size of
segments and sub-segments.
Research Methodology
1.1. Secondary Research
The secondary research study involves various sources and databases used
to analyze and collect information for the market-oriented survey of a specific
market. We use multiple databases for our exhaustive secondary research, such
as Factiva, Dun & Bradstreet, Bloomberg, Research article, Annual reports,
Press Release, and SEC filings of significant companies. Apart from this, a
dedicated set of teams continuously extracts data of key industry players and
makes an extensive and unique segmentation related to the latest market
development.
1.2. Primary Research
The primary research includes gathering data from specific domain
experts through a detailed questionnaire, emails, telephonic interviews, and
web-based surveys. The primary interviewees for this study include an expert
from the demand and supply side, such as CEOs, VPs, directors, sales heads, and
marketing managers of tire 1,2, and 3 companies across the globe.
1.3. Data Triangulation
The data triangulation is very important for any market study, thus we
at Zettabyte Analytics focus on at least three sources to ensure a high level
of accuracy. The data is triangulated by studying various factors and trends
from both supply and demand side. All the reports published and stored in our
repository follows a detailed process to obtain a reliable insight for our
clients.
1.4. In-House Verification
To validate the segmentation
and verify the data collected, our market expert ensures whether our research
analyst is considering fine distinction before analyzing the market.
1.5. Reporting
In the end,
presenting our research reports complied in a different format for straightforward
valuation such as ppt, pdf, and excel data pack is done.
+1 716 953 3077
sales@zettabyteanalytics.com
109 S Warren St, Syracuse, NY 13202, United States